Table 4.

Completed clinical trials based on combination therapy with anti-PD-1/PD-L1 therapy for renal cell carcinoma (RCC) registered in ClinicalTrials.gov (June 2022)

Agents	Phase	Participant number	Allocation	Dose	Location	NCT number
Nivolumab Ipilimumab	2	118	Randomized	–	USA Australia Chile	NCT03029780
Nivolumab Ipilimumab Sunitinib Pazopanib	1	194	Non-Randomized	5.0 mg/kg 1 mg 50 mg 800 mg	Canada USA	NCT01472081
X4P-001 Nivolumab	1/2	9	N/A	400 mg 240 mg	USA	NCT02923531
IL-2 Nivolumab	1/2	13	N/A	600,000 IU/kg 240 mg	USA	NCT02989714
Nivolumab SBRT	2	69	N/A	240 mg 30 Gy	Italy	NCT03469713
Nivolumab Ipilimumab Sunitinib Pazopanib	2	200	Randomized	5.0 mg/kg 1 mg 50 mg 800 mg	France	NCT02960906
Nivolumab Ipilimumab	4	211	Non-Randomized	–	USA	NCT02982954
Nivolumab CB-839	1/2	118	Non-Randomized	–	USA	NCT02771626
Nivolumab Ipilimumab SBRT	2	29	N/A	–	USA	NCT03065179
Ibrutinib Nivolumab	1/2	31	N/A	–	USA	NCT02899078
Tivozanib Nivolumab	1/2	28	N/A	– 240 mg	France	NCT03136627
Varlilumab Nivolumab	1/2	175	N/A	3 mg/kg 240 mg	USA	NCT02335918
Cabiralizumab Nivolumab	1	313	Non-Randomized	2 mg/kg 3 mg/kg	USA	NCT02526017
Nivolumab ABI-009	1/2	34	N/A	3 mg/kg 100 mg/m2	USA	NCT03190174
Pembrolizumab Axitinib	1	52	N/A	2 mg/kg 3–5 mg	USA	NCT02133742
Bevacizumab Pembrolizumab	1/2	61	Non-Randomized	10 mg 200 mg	USA	NCT02348008
Pembrolizumab Ipilimumab or PegIFN-2b	1/2	295	Randomized	200 mg 50–100 mg –	UK	NCT02089685
Pazopanib Pembrolizumab	1	42	Randomized	200 mg 10 mg/kg	USA	NCT02014636
Pembrolizumab Radiotherapy	1/2	30	N/A	200 mg 18–20 Gy	Australia	NCT02855203
Pembrolizumab INCB050465 Itacitinib	1	159	Randomized	200 mg – –	USA	NCT02646748
Pembrolizumab INCB024360	1/2	444	Non-Randomized	25 mg –	USA	NCT02178722
Atezolizumab Bevacizumab	3	915	Randomized	1200 mg 15 mg/kg	International	NCT02420821
Atezolizumab Bevacizumab	2	305	Randomized	1200 mg 15 mg/kg	International	NCT01984242
Atezolizumab Bevacizumab RO6874281	1	69	Randomized	840 mg 10 mg/kg 5 mg	International	NCT03063762
Ciforadenant Atezolizumab	1	502	Randomized	100–200 mg –	Canada USA Australia	NCT02655822
Avelumab Cabozantinib	1	12	N/A	10 mg/kg 20–60 mg	USA	NCT03200587
Avelumab Axitinib	1	55	N/A	5–10 mg/kg 3–5 mg	Japan USA UK	NCT02493751
Durvalumab Tremelimumab	1	29	N/A	– –	USA	NCT02762006
MEDI0680 Durvalumab Nivolumab	1/2	97	Randomized	0.1–20 mg/kg 3–10 mg/kg 240 mg	International	NCT02118337
PolyICLC Durvalumab Tremelimumab	1/2	58	Non-Randomized	–	USA	NCT02643303

NA